Axsome Therapeutics Inc
AXSM102.874USD
-0.146-0.14%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
5.06BCap. mercado
PérdidaP/E TTM
Más Datos de Axsome Therapeutics Inc Compañía
Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in developing and delivering therapies for central nervous system (CNS), conditions that have limited treatment options. The Company's two commercial products and development programs are Auvelity and Sunosi. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. AXS-05 is an oral, investigational NMDA receptor antagonist with multimodal activity under development for the treatment of Alzheimer's disease agitation (AD agitation) and smoking cessation. AXS-07 is an oral, rapidly absorbed, multi-mechanistic, investigational medicine under development for the acute treatment of migraine.
Información de la empresa
Símbolo de cotizaciónAXSM
Nombre de la empresaAxsome Therapeutics Inc
Fecha de salida a bolsaNov 19, 2015
Director ejecutivoDr. Herriot Tabuteau, M.D.
Número de empleados683
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 19
DirecciónOne World Trade Center, 29Th Floor
CiudadNEW YORK
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal10007
Teléfono12123323241
Sitio Webhttps://www.axsome.com/
Símbolo de cotizaciónAXSM
Fecha de salida a bolsaNov 19, 2015
Director ejecutivoDr. Herriot Tabuteau, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Independent Director
Independent Director
167.67K
--
Mr. Nick Pizzie, CPA
Mr. Nick Pizzie, CPA
Chief Financial Officer
Chief Financial Officer
42.67K
-1.00%
Mr. Mark E. Saad
Mr. Mark E. Saad
Independent Director
Independent Director
10.30K
--
Dr. Herriot Tabuteau, M.D.
Dr. Herriot Tabuteau, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
7.23K
--
Mr. Mark L. Jacobson
Mr. Mark L. Jacobson
Chief Operating Officer
Chief Operating Officer
5.78K
--
Mr. Hunter Murdock
Mr. Hunter Murdock
General Counsel
General Counsel
--
--
Dr. Susan M. (Sue) Mahony, Ph.D.
Dr. Susan M. (Sue) Mahony, Ph.D.
Independent Director
Independent Director
--
--
Dr. Mark Coleman, M.D.
Dr. Mark Coleman, M.D.
Lead Independent Director
Lead Independent Director
--
--
Mr. Ari Maizel
Mr. Ari Maizel
Chief Commercial Officer
Chief Commercial Officer
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Roger A. Jeffs, Ph.D.
Dr. Roger A. Jeffs, Ph.D.
Independent Director
Independent Director
167.67K
--
Mr. Nick Pizzie, CPA
Mr. Nick Pizzie, CPA
Chief Financial Officer
Chief Financial Officer
42.67K
-1.00%
Mr. Mark E. Saad
Mr. Mark E. Saad
Independent Director
Independent Director
10.30K
--
Dr. Herriot Tabuteau, M.D.
Dr. Herriot Tabuteau, M.D.
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
7.23K
--
Mr. Mark L. Jacobson
Mr. Mark L. Jacobson
Chief Operating Officer
Chief Operating Officer
5.78K
--
Mr. Hunter Murdock
Mr. Hunter Murdock
General Counsel
General Counsel
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2023
FY2023Q4
FY2023Q3
Por negocioUSD
Nombre
Ganancia
Proporción
Auvelitv
96.23M
79.23%
Sunosi
24.13M
19.86%
Sunosi royality revenue
1.10M
0.91%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
119.41M
98.31%
Outside of the United States
2.05M
1.69%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Auvelitv
96.23M
79.23%
Sunosi
24.13M
19.86%
Sunosi royality revenue
1.10M
0.91%
Estadísticas de accionistas
Actualizado: sáb., 12 de jul
Actualizado: sáb., 12 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Antecip Capital, L.L.C.
14.92%
The Vanguard Group, Inc.
7.86%
BlackRock Institutional Trust Company, N.A.
6.03%
RTW Investments L.P.
5.94%
BVF Partners L.P.
3.43%
Other
61.82%
Accionistas
Accionistas
Proporción
Antecip Capital, L.L.C.
14.92%
The Vanguard Group, Inc.
7.86%
BlackRock Institutional Trust Company, N.A.
6.03%
RTW Investments L.P.
5.94%
BVF Partners L.P.
3.43%
Other
61.82%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
33.54%
Investment Advisor/Hedge Fund
22.21%
Corporation
14.92%
Hedge Fund
14.24%
Research Firm
2.73%
Private Equity
1.51%
Individual Investor
1.39%
Pension Fund
1.17%
Sovereign Wealth Fund
0.82%
Other
7.48%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
614
46.10M
93.63%
-4.69M
2025Q1
613
46.35M
94.71%
-3.83M
2024Q4
570
46.09M
94.52%
-5.46M
2024Q3
540
47.31M
97.60%
-6.48M
2024Q2
526
49.58M
103.45%
-2.44M
2024Q1
512
47.53M
101.57%
-4.95M
2023Q4
484
47.45M
101.62%
-3.96M
2023Q3
475
47.05M
100.91%
-2.63M
2023Q2
475
45.53M
98.82%
+628.64K
2023Q1
467
40.73M
95.65%
-3.70M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Antecip Capital, L.L.C.
7.34M
14.92%
--
--
Apr 14, 2025
The Vanguard Group, Inc.
3.87M
7.86%
-26.20K
-0.67%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
2.97M
6.03%
-40.30K
-1.34%
Mar 31, 2025
RTW Investments L.P.
2.92M
5.94%
-1.13M
-27.86%
Mar 31, 2025
BVF Partners L.P.
1.69M
3.43%
+302.16K
+21.77%
Mar 31, 2025
Macquarie Investment Management
976.26K
1.98%
+12.21K
+1.27%
Mar 31, 2025
Geode Capital Management, L.L.C.
934.85K
1.9%
+22.32K
+2.45%
Mar 31, 2025
Fidelity Management & Research Company LLC
916.73K
1.86%
+275.45K
+42.95%
Mar 31, 2025
State Street Global Advisors (US)
906.02K
1.84%
-41.23K
-4.35%
Mar 31, 2025
Fairmount Funds Management LLC
815.18K
1.66%
-653.81K
-44.51%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
SPDR S&P Pharmaceuticals ETF
3.7%
ALPS Medical Breakthroughs ETF
3.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.62%
Tema Neuroscience and Mental Health ETF
2.52%
iShares U.S. Pharmaceuticals ETF
2.17%
Virtus LifeSci Biotech Products ETF
1.89%
First Trust Mid Cap Growth AlphaDEX Fund
0.6%
iShares Health Innovation Active ETF
0.59%
Invesco Nasdaq Biotechnology ETF
0.57%
ProShares Ultra Nasdaq Biotechnology
0.57%
Ver más
SPDR S&P Pharmaceuticals ETF
Proporción3.7%
ALPS Medical Breakthroughs ETF
Proporción3.47%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporción2.62%
Tema Neuroscience and Mental Health ETF
Proporción2.52%
iShares U.S. Pharmaceuticals ETF
Proporción2.17%
Virtus LifeSci Biotech Products ETF
Proporción1.89%
First Trust Mid Cap Growth AlphaDEX Fund
Proporción0.6%
iShares Health Innovation Active ETF
Proporción0.59%
Invesco Nasdaq Biotechnology ETF
Proporción0.57%
ProShares Ultra Nasdaq Biotechnology
Proporción0.57%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
